IS5875A - Ásetnar fenýlafleiður, framleiðsla þeirra og notkun - Google Patents

Ásetnar fenýlafleiður, framleiðsla þeirra og notkun

Info

Publication number
IS5875A
IS5875A IS5875A IS5875A IS5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A IS 5875 A IS5875 A IS 5875A
Authority
IS
Iceland
Prior art keywords
established
production
phenyl derivatives
phenyl
derivatives
Prior art date
Application number
IS5875A
Other languages
English (en)
Other versions
IS2215B (is
Inventor
H. Dahl Bjarne
Christophersen Palle
Original Assignee
Neurosearch A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch A/S filed Critical Neurosearch A/S
Publication of IS5875A publication Critical patent/IS5875A/is
Publication of IS2215B publication Critical patent/IS2215B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IS5875A 1998-10-22 2001-03-02 Setnar fenýlafleiður, framleiðsla þeirra og notkun IS2215B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA199801362 1998-10-22
PCT/DK1999/000575 WO2000024707A1 (en) 1998-10-22 1999-10-19 Substituted phenyl derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
IS5875A true IS5875A (is) 2001-03-02
IS2215B IS2215B (is) 2007-03-15

Family

ID=8104026

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5875A IS2215B (is) 1998-10-22 2001-03-02 Setnar fenýlafleiður, framleiðsla þeirra og notkun

Country Status (27)

Country Link
US (1) US6706749B2 (is)
EP (2) EP1123274B1 (is)
JP (2) JP3960754B2 (is)
KR (1) KR100799892B1 (is)
CN (1) CN1263733C (is)
AP (1) AP2001002103A0 (is)
AT (1) ATE286021T1 (is)
AU (1) AU759275B2 (is)
BR (1) BR9914638A (is)
CA (1) CA2342626A1 (is)
DE (1) DE69922986T2 (is)
EE (1) EE04849B1 (is)
ES (1) ES2235522T3 (is)
HU (1) HUP0103673A3 (is)
IL (2) IL141479A0 (is)
IS (1) IS2215B (is)
NO (1) NO20011956L (is)
NZ (1) NZ510098A (is)
OA (1) OA11665A (is)
PL (1) PL198852B1 (is)
PT (1) PT1123274E (is)
RU (1) RU2218328C2 (is)
SK (1) SK5222001A3 (is)
TR (1) TR200101126T2 (is)
UA (1) UA73284C2 (is)
WO (1) WO2000024707A1 (is)
ZA (1) ZA200101824B (is)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10102977A1 (de) 2001-01-23 2002-08-01 Thomas Jentsch Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose
DK1360504T3 (da) * 2001-01-23 2007-01-29 Pharmos Bioscience As Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom
WO2003000245A1 (en) * 2001-06-22 2003-01-03 Poseidon Pharmaceuticals A/S Compounds for use in disorders associated with mast cell or basophil activity
US20050003455A1 (en) * 2001-08-08 2005-01-06 Yasunobu Okada Remedies for heart diseases
US7078423B2 (en) 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US7087631B2 (en) 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7291603B2 (en) 2002-07-24 2007-11-06 Ptc Therapeutics, Inc. Nucleoside compounds and their use for treating cancer and diseases associated with somatic mutations
JP2005537336A (ja) * 2002-08-01 2005-12-08 ニューロサーチ、アクティーゼルスカブ 抗血管新生治療に応答する疾患の治療に有用な化合物
EP1537075B1 (en) * 2002-09-05 2009-07-01 Neurosearch A/S Diarylurea derivatives and their use as chloride channel blockers
AU2003258491A1 (en) * 2002-09-05 2004-03-29 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
WO2004046090A2 (en) 2002-11-21 2004-06-03 Neurosearch A/S Aryl ureido derivatives and their medical use
WO2004058722A1 (en) * 2002-12-24 2004-07-15 Arena Pharmaceuticals, Inc. Diarylamine and arylheteroarylamine pyrazole derivatives as modulators of 5ht2a
ZA200508828B (en) * 2003-06-17 2008-01-30 Neurosearch As Diphenylurea derivatives and their use as a chloride channel blockers
US8754238B2 (en) 2003-07-22 2014-06-17 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
WO2005023237A1 (en) 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of cardiac arrhythmias
WO2005023238A1 (en) * 2003-09-04 2005-03-17 Poseidon Pharmaceuticals A/S Erg channel openers for the treatment of hyperexcitability-related neuronal diseases
EP1727803B3 (en) * 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
RU2420520C2 (ru) * 2004-04-02 2011-06-10 Прана Биотехнолоджи Лимитэд Неврологически-активные составы
MXPA06011236A (es) 2004-04-02 2007-01-16 Prana Biotechnology Ltd Compuestos neurologicamente activos.
AU2005245412B2 (en) * 2004-05-12 2011-08-04 Protamed, Inc. Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
PE20061130A1 (es) 2004-11-19 2007-01-05 Arena Pharm Inc Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
US20080015223A1 (en) * 2004-12-03 2008-01-17 Arena Pharmaceuticals, Inc. Pyrazole Derivatives as Modulators of the 5-Ht2a Serotonin Receptor Useful for the Treatment of Disorders Related Thereto
TWI367098B (en) * 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
WO2006076592A1 (en) 2005-01-14 2006-07-20 Cgi Pharmaceuticals, Inc. 1,3 substituted diaryl ureas as modulators of kinase activity
WO2006078610A1 (en) * 2005-01-19 2006-07-27 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis or treatment of progressive multifocal leukoencephalopathy
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
MX2008011409A (es) * 2006-03-14 2008-09-22 Neurosearch As Derivados de difenilurea y su uso como bloqueadores de canal de cloruro o moduladores del canal bkca.
US20100144693A1 (en) 2006-04-14 2010-06-10 Prana Biotechnology Limited Method of treatment of age-related macular degeneration (amd)
US8148418B2 (en) 2006-05-18 2012-04-03 Arena Pharmaceuticals, Inc. Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
USRE45336E1 (en) 2006-05-18 2015-01-13 Arena Pharmaceuticals, Inc. Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ594353A (en) 2006-05-18 2013-02-22 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
JP5393677B2 (ja) 2007-08-15 2014-01-22 アリーナ ファーマシューティカルズ， インコーポレイテッド ５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20100286149A1 (en) * 2007-11-26 2010-11-11 Antonio Nardi Novel benzamide derivatives useful as potassium channel modulators
US20110021538A1 (en) * 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
HRP20180589T1 (hr) * 2008-10-28 2018-05-18 Arena Pharmaceuticals, Inc. Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
WO2011022028A2 (en) * 2009-05-18 2011-02-24 Tufts University Small molecule antagonists of phosphatidylinositol-3, 4, 5-triphosphate (pip3) and uses thereof
GB0915196D0 (en) 2009-09-01 2009-10-07 King S College London Therapeutic compounds and their use
EP2493468A1 (en) * 2009-10-30 2012-09-05 Sanofi Amino-benzoic acid derivatives for use in the treatment of dihydrogenase-related disorders
US8980891B2 (en) 2009-12-18 2015-03-17 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
RU2434851C1 (ru) * 2010-07-22 2011-11-27 Александр Васильевич Иващенко Циклические n, n'-диарилтиомочевины или n, n'-диарилмочевины - антагонисты андрогенных рецепторов, противораковое средство, способ получения и применения
US9834537B2 (en) 2013-11-27 2017-12-05 Korea Institute Of Science And Technology Compounds as chloride channel blocking agent
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
RU2017145976A (ru) 2015-06-12 2019-07-15 Аксовант Сайенсиз Гмбх Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh) 2015-07-15 2017-06-16 Axovant Sciences Gmbh 用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
EP3622953B1 (en) 2016-05-17 2021-03-17 Scandion Oncology A/S Combination treatment of cancer
CA3069720A1 (en) 2017-07-11 2019-01-17 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
CA3194203A1 (en) * 2020-09-14 2022-03-17 Genzyme Corporation Carboxylic acid-containing compounds as modulators of bis-phosphoglycerate mutase for the treatment of sickle cell disease
CA3221557A1 (en) 2021-06-14 2022-12-22 Peter Michael Vestlev Combination treatments for cancer patients and methods for identifying same
WO2022263404A1 (en) 2021-06-14 2022-12-22 Scandion Oncology A/S Methods of increasing the plasma drug exposure of anticancer agents
EP4104834A1 (en) 2021-06-14 2022-12-21 Scandion Oncology A/S Combination treatments for cancer patients and methods for identifying same
TW202321205A (zh) 2021-07-16 2023-06-01 丹麥商斯坎丁腫瘤公司 Sco-101的熱力穩定形式
CN117229258B (zh) * 2022-06-07 2024-07-19 杭州壹瑞医药科技有限公司 N-四唑基芳基脲类衍生物及其制备方法和应用
WO2024013058A1 (en) 2022-07-11 2024-01-18 Scandion Oncology A/S Salts of sco-101 and methods involving salts
WO2025125679A1 (en) 2023-12-15 2025-06-19 Scandion Oncology A/S Improved anti-cancer treatment regimen
CN119039190B (zh) * 2024-09-20 2026-03-10 上海信诺维生物医药有限公司 一种wrn抑制剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055786A (en) * 1963-07-12 1967-01-18 Ici Ltd Urea derivatives
FR2100943A1 (en) * 1970-07-23 1972-03-24 Ici Ltd O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
CA1156250A (en) * 1979-10-15 1983-11-01 Eastman Kodak Company Cyan dye-forming couplers
DE3100575A1 (de) * 1981-01-10 1982-09-02 Dr. Karl Thomae Gmbh, 7950 Biberach "neue benzoesaeuren, ihre herstellung und ihre verwendung als arzneimittel"
ATE68785T1 (de) 1985-07-31 1991-11-15 Hoechst Ag N-substituierte 5-nitroanthranilsaeuren, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen.
US4889612A (en) 1987-05-22 1989-12-26 Abbott Laboratories Ion-selective electrode having a non-metal sensing element
US4921997A (en) * 1988-06-15 1990-05-01 Montefiore Medical Center Method of synthesis and novel compounds for pharmaceutical uses
WO1991013874A1 (fr) 1990-03-07 1991-09-19 Rhone-Poulenc Rorer S.A. Derives de glycinamide, leur preparation et les medicaments les contenant
US5489612A (en) 1991-08-23 1996-02-06 The University Of Alabama At Birmingham Research Foundation Calixarene chloride-channel blockers
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
CA2137755C (en) * 1994-06-07 2002-07-02 William H. Waugh Palliation of sickle cell disorders by phenylurea, benzylurea, or phenylethylurea or by a homolog ring-substituted with one methoxyl, methyl, or hydroxyl radical
US5559151A (en) 1994-11-30 1996-09-24 Allergan Method for reducing intraocular pressure in the mammalian eye by administration of chloride channel blockers
DE4447096C2 (de) * 1994-12-29 1998-12-03 Rehau Ag & Co Stabilisierte chlorhaltige Polymerisate und Verwendung von funktionellen Harnstoff-Derivaten als Stabilisatoren
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
TR199802136T2 (xx) * 1996-04-23 2001-06-21 Vertex Pharmaceuticals Incorporated �MPDH enzimi inhibit�rleri olarak �re t�revleri.
CA2255858C (en) * 1996-05-24 2007-09-11 Neurosearch A/S Phenyl derivatives containing an acidic group, their preparation and their use as chloride channel blockers
CZ295822B6 (cs) * 1997-04-22 2005-11-16 Neurosearch A/S Substituované fenylderiváty, způsob jejich přípravy a použití a farmaceutické přípravky s jejich obsahem
US6093742A (en) * 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
IL136737A0 (en) * 1997-12-22 2001-06-14 Bayer Ag Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas

Also Published As

Publication number Publication date
JP3960754B2 (ja) 2007-08-15
DE69922986T2 (de) 2005-07-07
HUP0103673A3 (en) 2003-03-28
NO20011956D0 (no) 2001-04-20
ATE286021T1 (de) 2005-01-15
HUP0103673A2 (hu) 2002-02-28
AU6325999A (en) 2000-05-15
WO2000024707A1 (en) 2000-05-04
NO20011956L (no) 2001-04-20
IL141479A0 (en) 2002-03-10
HK1040699A1 (en) 2002-06-21
KR100799892B1 (ko) 2008-01-31
BR9914638A (pt) 2001-07-03
EE04849B1 (et) 2007-06-15
OA11665A (en) 2004-12-08
IL141479A (en) 2006-08-20
AP2001002103A0 (en) 2001-03-31
EP1123274B1 (en) 2004-12-29
AU759275B2 (en) 2003-04-10
NZ510098A (en) 2003-09-26
EP1514867A2 (en) 2005-03-16
EE200100185A (et) 2002-08-15
PL347371A1 (en) 2002-04-08
ZA200101824B (en) 2002-03-05
IS2215B (is) 2007-03-15
PL198852B1 (pl) 2008-07-31
DE69922986D1 (de) 2005-02-03
US6706749B2 (en) 2004-03-16
US20020032210A1 (en) 2002-03-14
EP1514867A3 (en) 2005-03-23
CN1322194A (zh) 2001-11-14
UA73284C2 (en) 2005-07-15
SK5222001A3 (en) 2002-05-09
EP1123274A1 (en) 2001-08-16
ES2235522T3 (es) 2005-07-01
CA2342626A1 (en) 2000-05-04
RU2218328C2 (ru) 2003-12-10
CN1263733C (zh) 2006-07-12
PT1123274E (pt) 2005-04-29
JP2002528432A (ja) 2002-09-03
TR200101126T2 (tr) 2001-09-21
KR20010080270A (ko) 2001-08-22
JP2003246773A (ja) 2003-09-02

Similar Documents

Publication Publication Date Title
IS5875A (is) Ásetnar fenýlafleiður, framleiðsla þeirra og notkun
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20012567D0 (no) Azepinoindolderivater, fremstilling og anvendelse derav
IS2040B (is) Pýrasólínafleiður, framleiðsla þeirra og notkun sem lyfja
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
ATE435861T1 (de) 12,13-cyclopropan-epothilonderivate
NO20021379D0 (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
DE69924799D1 (de) Miederhose
DK1073672T3 (da) Antipicornavirale forbindelser, deres fremstilling og anvendelse
IS2174B (is) Setnar fenýl-píperasín afleiður, framleiðsla þeirra og notkun
NO20013237D0 (no) 3,3-biarylpiperidin og 2,2-biarylmorfolinderivater
DK1202996T3 (da) Titanforbindelser, fremstilling og anvendelse heraf
IS7829A (is) Nýjar 1,4-díazabísýklóalkan-afleiður, framleiðslaþeirra og notkun
NO20003825L (no) 1,3,4 - oxadiazolonderivater
DK1025100T3 (da) 3-substituerede tetrahydropyridopyrimidinonderivater, fremstilling og anvendelsen heraf
IS5731A (is) 4, 5, 6 og 7-indól og indólín afleiður, framleiðsla þeirra og notkun
IS5940A (is) Bensófúran afleiður, framleiðsla þeirra og notkun
NO20006479D0 (no) Tienopyridinforbindelser, deres fremstilling og anvendelse
IS6403A (is) Nýjar heteróarýl afleiður, framleiðsla þeirra og notkun
NO996156L (no) Substituerte cykloheptener, deres fremstilling og anvendelse
DK1043306T3 (da) 3-amino-3-arylpropan-1-ol-derivater, fremstilling og anvendelse af disse
NO20020404D0 (no) Streptograminderivater, deres produksjon og forbindelser derav
IS7131A (is) Nýjar 2,4-díamínóþíasól afleiður
DK1123274T3 (da) Substituerede phenylderivater, deres fremstilling og anvendelse